Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
Xiangyi Kong,1,2,* Kai Zhang,3,* Xiangyu Wang,1,4,* Xue Yang,1,* Yalun Li,5 Jie Zhai,1 Zeyu Xing,1 Yihang Qi,1 Ran Gao,1 Xiaoli Feng,6 Jing Wang,1 Yi Fang11Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, C...
Main Authors: | Kong X, Zhang K, Wang X, Yang X, Li Y, Zhai J, Xing Z, Qi Y, Gao R, Feng X, Wang J, Fang Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-07-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/mechanism-of-trastuzumab-resistance-caused-by-her-2-mutation-in-breast-peer-reviewed-article-CMAR |
Similar Items
-
Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
by: Chen Y, et al.
Published: (2024-07-01) -
Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
by: Lang Y, et al.
Published: (2022-12-01) -
A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
by: Hong J, et al.
Published: (2019-04-01) -
Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01) -
Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)